Clinical guideline recommends atomoxetine for ADHD with cannabis use disorder but finds it does not reduce cannabis use itself
A clinical practice guideline using the GRADE approach recommends atomoxetine to improve ADHD symptoms in patients with cannabis use disorder (weak recommendation) but not to reduce cannabis use itself.
Quick Facts
What This Study Found
For ADHD with cannabis use disorder: atomoxetine is weakly recommended to improve ADHD symptoms but weakly recommended against reducing cannabis use. For ADHD with any SUD: both psychostimulants and atomoxetine are weakly recommended for ADHD symptoms but not for reducing substance use. Atomoxetine and psychostimulants are considered safe in patients with SUD (strong recommendation). Neither reduces treatment retention (strong recommendation against).
Key Numbers
Cannabis-specific: atomoxetine recommended for ADHD symptoms (weak) but not for cannabis use (weak against). Safety of both medication classes in SUD patients: strong recommendation.
How They Did This
Clinical practice guideline synthesizing pharmacological and psychosocial interventions for adults with ADHD and comorbid SUD, using the GRADE approach for recommendation strength.
Why This Research Matters
ADHD and substance use disorders frequently co-occur, but clinicians often hesitate to prescribe ADHD medications due to abuse concerns. This guideline provides evidence-based recommendations with safety reassurance.
The Bigger Picture
The finding that ADHD medications can safely improve ADHD symptoms in patients with substance use disorders, even if they do not reduce substance use, supports a treat-the-ADHD approach that may indirectly benefit substance use outcomes.
What This Study Doesn't Tell Us
Mostly weak recommendations reflecting limited evidence. Few large, multisite RCTs. Cannabis-specific evidence is particularly sparse. GRADE approach penalizes for imprecision and indirectness. May not reflect all clinical scenarios.
Questions This Raises
- ?Would treating ADHD symptoms indirectly reduce cannabis use over time?
- ?Should lisdexamfetamine be evaluated specifically for ADHD+CUD?
- ?Are there subgroups that respond better to specific medications?
Trust & Context
- Key Stat:
- Atomoxetine safe and effective for ADHD symptoms in cannabis use disorder
- Evidence Grade:
- GRADE-based clinical practice guideline, but most recommendations are weak due to limited evidence.
- Study Age:
- Published in 2022.
- Original Title:
- Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.
- Published In:
- Adicciones, 34(2), 168-178 (2022)
- Authors:
- Cunill, Ruth(2), Castells, Xavier, González-Pinto, Ana(8), Arrojo, Manuel, Bernardo, Miquel, Sáiz, Pilar A, Flórez, Gerardo, Torrens, Marta, Tirado-Muñoz, Judit, Fonseca, Francia, Arranz, Belén, Garriga, Marina, Goikolea, Jose Manuel, Zorrilla, Iñaki, Becoña, Elisardo, López, Ana, San, Luis
- Database ID:
- RTHC-03779
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Can ADHD medications be safely used in people who use cannabis?
Yes. This guideline strongly recommends that both atomoxetine and psychostimulants are safe in patients with substance use disorders, including cannabis use disorder.
Will treating ADHD reduce cannabis use?
Current evidence does not support using ADHD medications specifically to reduce cannabis use. However, atomoxetine can improve ADHD symptoms, which may indirectly benefit overall functioning.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-03779APA
Cunill, Ruth; Castells, Xavier; González-Pinto, Ana; Arrojo, Manuel; Bernardo, Miquel; Sáiz, Pilar A; Flórez, Gerardo; Torrens, Marta; Tirado-Muñoz, Judit; Fonseca, Francia; Arranz, Belén; Garriga, Marina; Goikolea, Jose Manuel; Zorrilla, Iñaki; Becoña, Elisardo; López, Ana; San, Luis. (2022). Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.. Adicciones, 34(2), 168-178. https://doi.org/10.20882/adicciones.1569
MLA
Cunill, Ruth, et al. "Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.." Adicciones, 2022. https://doi.org/10.20882/adicciones.1569
RethinkTHC
RethinkTHC Research Database. "Clinical practice guideline on pharmacological and psycholog..." RTHC-03779. Retrieved from https://rethinkthc.com/research/cunill-2022-clinical-practice-guideline-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.